Product Description
please call me , to know more
AI Product Description
*The following content is generated by AI and is for reference only.
Saxagliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor widely utilized in the management of type 2 diabetes mellitus. Its chemical identity is defined by the molecular formula C17H25FN6O3, with a precise molecular weight of approximately 376.4 g/mol. The substance is uniquely identified by the CAS Registry Number 309593-68-2. Structurally, Saxagliptin features a pyrazine ring substituted with a fluorophenyl group and a pyrrolidine moiety, which facilitates high-affinity binding to the active site of the DPP-4 enzyme.
The primary therapeutic application of Saxagliptin involves enhancing glycemic control in adult patients with type 2 diabetes when used as an adjunct to diet and exercise. It functions by inhibiting the enzyme responsible for the rapid degradation of incretin hormones, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preventing this degradation, Saxagliptin increases circulating levels of these active hormones, which subsequently stimulate insulin secretion in a glucose-dependent manner while simultaneously suppressing inappropriate glucagon release. This dual mechanism helps lower blood glucose levels without significantly increasing the risk of hypoglycemia compared to some other antidiabetic agents.
Clinically, Saxagliptin is often prescribed either as monotherapy or in combination with other oral antidiabetic medications such as metformin, sulfonylureas, or thiazolidinediones. It is available commercially under various brand names, most notably Onglyza, depending on the region. The drug demonstrates favorable pharmacokinetic properties, including good oral bioavailability and a relatively short half-life, allowing for once-daily dosing. While generally well-tolerated, healthcare providers must monitor for potential adverse effects, including upper respiratory tract infections, nasopharyngitis, and headache. Furthermore, specific caution is advised regarding heart failure risks, as recent studies have indicated a possible association between DPP-4 inhibitors and hospitalization for heart failure in certain patient populations. Despite these considerations, Saxagliptin remains a valuable component of modern diabetes treatment protocols due to its efficacy, safety profile, and ease of administration.